Evidence regarding SGLT-2 inhibitors for the management of diabetic dyslipidemia

We thank doctors Seetharaman and Joshi for their interest in our recently published Expert Consensus Statement on Management of Diabetic Dyslipidemia in Indians from the Lipid Association of India.1 They have expressed concerns about possible adverse effects of treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors on the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma.

Source: Journal of Clinical Lipidology - April 28, 2023 Category: Lipidology Authors: P. Barton Duell, Raman Puri, Vimal Mehta, Nathan D. Wong Tags: Letter to the Editor Source Type: research